Csrnewsdaily.com Issues Investment Alert On (NASDAQ: CLSN), (OTCQB:...

CLSN) plunged 81.55% to $1.48 on a traded volume of 24.20 million shares. The Company said that in combination with radiofrequency ablation did not meet the primary endpoint of the Phase III HEAT Study in patients with hepatocellular carcinoma, also known as primary liver cancer.

http://www.macreportmedia.com/ViewSubmission.aspx?submissionRequest=20802